N.M. Admin. Code § 16.19.4.7 - DEFINITIONS
A.
"A
year" begins with the pharmacist's birth month and ends the last day of
the pharmacist's birth month the following year.
B.
"Accredited Provider" An
institution, organization or agency that has been recognized by the
Accreditation Council for Pharmacy Education, in accord with its policy and
procedures, as having demonstrated compliance with the standards which are
indicative of the Provider's capability to develop and deliver quality
continuing pharmacy education.
C.
"Activity" as used in the ACPE criteria for quality and these
regulations, the term refers to an individual educational experience or program
such as a lecture, home study course, workshop, seminar, symposium,
etc.
D.
"Alternate
supervising physician" means a physician who holds a current
unrestricted license, is a cosignatory on the notification of supervision,
agrees to act as the supervising physician in the supervising physician's
absence, or expand the "scope of practice or sites of practice" of the
pharmacist clinician and is approved by the board.
E.
"Board" means the New Mexico
board of pharmacy.
F.
"Consultation" means communication in person, telephonically, by
two-way radio, by e-mail or by other electronic means.
G.
"Contact hour" means a unit
of measure equivalent to 60 minutes of participation in an approved organized
learning experience or activity.
H.
"Continuing education unit (CEU)" means ten contact hours of
participation or it ' s equivalent in an organized continuing education
activity sponsored by an accredited provider.
I.
"Continuing pharmacy education
(CPE)" means a structured education activity offered by an accredited
provider, designed or intended to support the continuing development of
pharmacies or pharmacy technicians to maintain and enhance their competence.
Continuing pharmacy education should promote problem-solving and critical
thinking and be applicable to the practice of pharmacy.
J.
"Continuing professional development
(CPD)" means the responsibility of individual pharmacists for systematic
maintenance, development and broadening of knowledge, skills and attitudes, to
ensure continuing competence as a professional, throughout their
careers.
K.
"Criteria for
quality" means continuing education provider shall show evidence of
adherence to the criteria adopted by the American council on pharmaceutical
education as indicative of the ability to provide continuing pharmaceutical
education activities; areas include: administrative and organization; budget
and resources; teaching staff; educational content management of activity;
method of delivery; facilities; evaluation mechanism.
L.
"Dangerous drug" means a drug
that, because of any potentiality for harmful effect or the methods of its use
or the collateral measures necessary to its use, is not safe except under the
supervision of a provider licensed by law to direct the use of such drug and
the drug prior to dispensing is required by federal law and state law to bear
the manufacturer's legend "Caution: Federal law prohibits dispensing without a
prescription;" or "Caution: federal law restricts this drug to use by or on the
order of a licensed veterinarian."; or "Rx only."
M.
"Guidelines or protocol"
means a written agreement between a pharmacist clinician or group of pharmacist
clinicians and a physician or group of physicians that delegates prescriptive
authority.
N.
"Initial
pharmacist licensure" means the license issued shall be valid for no
less than 24 months. The license will expire the last date of his/her birth
month that immediately follows the minimum 24 month time period.
O.
"Live programs" means CPE
activities that provide for direct interaction between faculty and participants
and may include lectures, symposia, live teleconferences, workshops,
etc.
P.
"Monitor dangerous
drug therapy" means to review the dangerous drug therapy regimen of
patients by a pharmacist clinician for the purpose of evaluating and rendering
advice regarding adjustment of the regimen. "Monitor dangerous drug therapy"
includes:
(1) collecting and reviewing patient
dangerous drug histories;
(2)
measuring and reviewing routine patient vital signs including pulse,
temperature, blood pressure and respiration;
(3) ordering and evaluating the results of
laboratory tests relating to dangerous drug therapy, including blood
chemistries and cell counts, controlled substance therapy levels, blood, urine,
tissue or other body fluids, culture and sensitivity tests when performed in
accordance with guidelines or protocols applicable to the practice setting
and;
(4) evaluating situations that
require the immediate attention of the physician and instituting or modifying
treatment procedures when necessary.
Q.
"Oversight committee" means a
joint committee made up of four members to hear issues regarding pharmacist
clinicians' prescriptive authority activities and supervising physicians'
direction of these activities.
R.
"Patient safety" means the prevention of healthcare errors and the
elimination or mitigation of patient injury caused by healthcare
errors.
S.
"Pharmaceutical
care" means the provision of drug therapy and other patient care
services related to drug therapy intended to achieve definite outcomes that
improve a patient's quality of life, including identifying potential and actual
drug-related problems, resolving actual drug-related problems and preventing
potential drug-related problems.
T.
"Pharmacist" means a person duly licensed by the board to engage
in the practice of pharmacy pursuant to the Pharmacy Act, Sections
61-11-1,
61-11-2,
61-11-4 to
61-11-28 NMSA 1978.
U.
"Pharmacist clinician" means
a pharmacist with additional training required by regulations adopted by the
board in consultation with the New Mexico medical board and the New Mexico
academy of physician assistants, who exercises prescriptive authority in
accordance with guidelines or protocol.
V.
"Pharmacist in charge" means
a pharmacist who accepts responsibility for the operation of a pharmacy in
conformance with all laws and rules pertinent to the practice of pharmacy and
the distribution of drugs and who is personally in full and actual charge of
the pharmacy and its personnel.
W.
"Practice of pharmacy" means continually optimizing medication
safety, patient wellness, and quality of services through the effective use of
pharmaceutical care and emerging technologies and competency-based and
performance-based training. The practice of pharmacy may include:
(1) Pharmaceutical dispensing including
product selection.
(2) specialty
pharmacy practice including pharmacists working for licensed pharmaceutical
manufacturers or wholesalers;
(3)
practice of telepharmacy within and across state lines;
(4) engaging in health care educational
activities;
(5) pharmacy-specific
academia;
(6) provision of those
acts or services necessary to provide pharmaceutical care in all areas of
patient care including patient counseling, prescriptive authority, drug
administration, primary care, medication therapy management, collaborative
practice, and monitoring dangerous drug therapy;
(7) inspecting on a full time basis to ensure
compliance with the practice of pharmacy;
(8) provision of pharmaceutical and drug
information services, as well as consultant pharmacy services;
(9) engaging in other phases of the
pharmaceutical profession including those with research or investigational or
dangerous drugs;
(10) engaging in
functions that relate directly to the administrative, advisory, or executive
responsibilities pursuant to the practice of pharmacy in this state;
(11) the responsibility for compounding and
labeling of drugs and devices;
(12)
the proper and safe storage of drugs and devices; and
(13) the maintenance of proper
records.
X.
"Practitioner" means a health care provider duly authorized by law
in New Mexico to prescribe dangerous drugs including controlled substances in
schedules II through V.
Y.
"Prescriptive authority" means the authority to prescribe,
administer, monitor or modify dangerous drug therapy.
Z.
"Professional judgment" means
a cognitive process, by a licensed pharmacist, that takes education, experience
and current standards of practice into consideration when drawing conclusions
and reaching decisions.
AA.
"Renewal period" means continuing education programs or activities
must be completed during the 24 month time period occurring between the last
day of the pharmacist's birth month and the last day of his/her birth month 2
years later.
BB.
"Scope of
practice" means those duties and limitations of duties placed upon a
pharmacist clinician and and includes a physician approved by the medical board
as an alternate supervising physician.
CC.
"Standard of care" means
care provided by a licensee that is within the accepted standard of care that
would be provided in a same or similar setting by a reasonably competent and
prudent licensee or registrant with similar education, training, and
experience.
DD.
"Supervising
physician" means a doctor, or group of doctors, of medicine or
osteopathy approved by the board to supervise a pharmacist clinician; and
includes a physician approved by the medical board as an alternate supervising
physician.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.